Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

McGovern, Rachel A; Thielen, Alexander; Mo, Theresa; More

AIDS . 24(16):2517-2525, October 23, 2010.

Bayesian network analyses of resistance pathways against efavirenz and nevirapine

Deforche, Koen; Camacho, Ricardo J; Grossman, Zehave; More

AIDS . 22(16):2107-2115, October 18, 2008.

Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection

Brumme, Zabrina L; Tao, Iris; Szeto, Sharon; More

AIDS . 22(11):1277-1286, July 11, 2008.

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients

Phillips, Elizabeth; Gutiérrez, Sonia; Jahnke, Natalie; More

AIDS . 21(12):1561-1568, July 31, 2007.

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors

Harrigan, P Richard; Mo, Theresa; Wynhoven, Brian; More

AIDS . 19(6):549-554, April 8, 2005.

Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy

Brumme, Zabrina L; Dong, Winnie WY; Yip, Benita; More

AIDS . 18(4):F1-F9, March 5, 2004.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy

Brumme, Zabrina L; Chan, Keith J; Dong, Winnie WY; More

AIDS . 16(14):1929-1933, September 27, 2002.

The M184 V mutation in HIV‐1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross‐resistance to nucleoside analogue RT inhibitors

Miller, Veronica; Stürmer, Martin; Staszewski, Schlomo; More

AIDS . 12(7):705-712, May 7, 1998.